MJ stock forecast, quote, news & analysis

Key Takeaways

• Amplify Alternative Harvest ETF (MJ) tracks the Prime Alternative Harvest Index, providing exposure to global companies in the cannabis and hemp ecosystem through a concentrated portfolio of 10 holdings.
• Top holding is CNBS at approximately 47%, followed by cannabis firms like TLRY (15%), emphasizing U.S. and Canadian producers.
• Net expense ratio of 0.75% with quarterly rebalancing; non-diversified structure heightens volatility tied to regulatory shifts.
• Dominant sector exposure to healthcare (around 74%) and consumer defensive (21%), aligned with medicinal and recreational cannabis trends.
• Recent performance reflects sector sensitivity to U.S. rescheduling momentum and Canadian market stabilization, amid ongoing supply pressures.
• Key risks include regulatory delays, oversupply in mature markets, and competition from intoxicating hemp products facing potential bans.

Amplify Alternative Harvest ETF (MJ) Overview

The Amplify Alternative Harvest ETF (MJ) seeks investment results that generally correspond, before fees and expenses, to the total return performance of the Prime Alternative Harvest Index. This passively managed, non-diversified fund employs a replication strategy, investing at least 80% of its net assets in index securities, including an affiliated ETF for U.S. exposure and global cannabis companies deriving at least 50% of revenue from legal cultivation, production, marketing, or distribution of cannabis or hemp products.

The fund holds 10 securities, with the top 10 comprising over 99% of assets. Key holdings include CNBS (Amplify Seymour Cannabis ETF, ~47%), TLRY (Tilray Brands, Inc., ~15%), Cronos Group Inc. (~8%), Canopy Growth Corp. (~7%), and SNDL Inc. (~6%). Sector allocations tilt heavily toward healthcare (~74%) and consumer defensive (~21%), with minor real estate and technology exposure. The portfolio is 100% small-cap focused and split roughly between U.S. (~56%) and Canada (~44%) issuers.

MJ's net expense ratio stands at 0.75%, reflecting a management fee waiver on acquired fund fees until 2027 (total gross 1.12%). The underlying index uses proprietary weighting—market cap or equal-based on cannabis engagement—and rebalances quarterly to maintain alignment with the evolving legal cannabis landscape.

Industry and Thematic Landscape

The cannabis sector encompasses cultivation, production, distribution, and related products for medicinal and recreational use, driven by progressive legalization. In North America, Canada’s mature recreational market grapples with oversupply and price compression, yet exports doubled in 2025 to over 240 tonnes, targeting Germany and Australia. The U.S. features 38 states with medical programs and 24 for recreational, but federal Schedule I status imposes 280E tax burdens, curbing cash flows despite projected $47 billion revenue by 2026.

Structural growth stems from medical acceptance for chronic pain, epilepsy, and other conditions, with global medical cannabis markets expanding at 22.9% CAGR through 2034. Catalysts include President Trump’s December 2025 executive order expediting Schedule III rescheduling—potentially unlocking $1.6–2.2 billion in annual after-tax cash flow—and a looming federal ban on intoxicating hemp-derived THC by late 2026, redirecting demand to regulated channels. Risks persist from regulatory delays, litigation, international competition, and supply gluts in Canada.

Performance and Positioning Snapshot

In recent market cycles, MJ has exhibited heightened volatility characteristic of the cannabis sector, with year-to-date declines around 14% amid broader equity gains, reflecting ongoing price pressures and regulatory uncertainty. Over the trailing 12 months, however, the ETF delivered positive returns exceeding 17–24%, buoyed by optimism around U.S. rescheduling progress and Canadian export surges.

Recent trading sessions showed modest rebounds tied to sector rotation into thematic growth areas, as investors positioned for potential tax relief under Schedule III and reduced hemp competition. MJ’s concentrated exposure amplified reactions to earnings from top holdings like TLRY and SNDL, alongside macroeconomic factors such as stabilizing wholesale prices in Canada and global medical demand upticks.

Trending AI Robots

Tickeron’s Trending AI Robots page showcases the platform’s top-performing AI trading bots under prevailing market conditions. Tickeron provides hundreds of AI bots scanning thousands of tickers across diverse strategies, timeframes, and performance metrics, from momentum and mean reversion to options trading. Only the strongest current performers—often displaying win rates above 60% and sharp risk-adjusted returns—appear in this curated section, helping investors identify adaptive tools for volatile sectors like cannabis ETFs. Explore the page to discover bots tailored to your trading style and receive actionable signals today.

2026 Outlook and Key Factors to Monitor

Looking to 2026, the cannabis sector—and MJ by extension—stands at a policy inflection point. The Trump administration’s executive order initiates Schedule III rescheduling, potentially alleviating 280E taxes and enhancing banking access for U.S. operators, though full implementation may face litigation and extend into 2027. This could free up $1.6–2.2 billion in annual cash flows, bolstering top holdings’ balance sheets and funding expansion.

Canadian producers, comprising much of MJ’s portfolio, benefit from stabilizing wholesale prices projected at $1.41/gram amid 27% export growth, though global competition from Germany and Australia poses risks. A federal hemp-THC ban by late 2026 may curb unregulated rivals, channeling demand to licensed channels and supporting U.S.-focused CNBS. Broader trends include medical cannabis CAGR of 22.9%, rising telemedicine in Europe, and product innovation like edibles.

Monitor earnings cycles for TLRY, SNDL, and peers; quarterly index rebalancing; capital inflows post-reform clarity; and competitive pressures from peers like MSOS. MJ’s 0.75% expense ratio remains competitive, but small-cap concentration amplifies macro risks such as interest rates and commodity-like pricing dynamics. Balanced positioning favors patient investors eyeing structural legalization tailwinds.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations